Dr David Planchard is a thoracic oncologist and head of the thoracic pathology committee at Gustave Roussy, where he is responsible for coordinating the management of patients with lung cancer, pleural mesothelioma or thymic tumours. He is also president of the International Center for Thoracic Cancers (CICT) , a health cooperation group combining Gustave Roussy, the Marie-Lannelongue Hospital and the Paris Saint-Joseph Hospital.
Expert in biomarkers and targeted treatment of bronchial cancers as well as in immunotherapy, he has been involved in more than 100 phase I, II and III trials and has published more than 130 articles in several renowned international journals.
Dr David Planchard co-directs clinical trials on thoracic tumours to develop a long-term clinical research strategy based on molecular screening. He coordinated the drafting of the latest European recommendations on the management of non-small cell lung cancer at an advanced stage ( ESMO Guidelines ) and participates in national and international congresses such as ESMO (European Society for Medical Oncology), ELCC (European Lung Cancer Congress), ASCO (American Society of Clinical Oncology) and WCLC (World Conference on Lung Cancer).
Dr Planchard is a member of the French-speaking pneumology society (SPLF) and of the French-speaking intergroup of thoracic oncology (IFCT), ESMO, ASCO, AACR (American Association for Cancer Research). He also participates in the national network for thymic tumours (RYTHMIC), the national expert network for malignant pleural mesothelioma (MESOCLIN) and the national network for the management of neuroendocrine tumours ( RENATEN ).